Drug intelligence / Profile preview

AP1081

Development stage: Phase 4
Lead developer: Halozyme
Modality: Small Molecules
Administration: Transdermal

Overview

**AP1081** was an investigational fixed-dose transdermal gel developed by Antares Pharma for female contraception. It combined the synthetic estrogen ethinyl estradiol with the progestin norelgestromin. Estrogenic and progestogenic signaling suppresses the hypothalamic-pituitary-gonadal axis, reducing gonadotropin release and inhibiting ovulation. The product was absorbed through the skin and was not identified as a marketed product or assigned an INN. ([go.drugbank.com](https://go.drugbank.com/drugs/DB05233))

Targets

PR (Progesterone receptor)ESR1 (ERα)ESR2 (ERβ)

Beyond the preview

Go deeper on AP1081.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP1081.